NASDAQ$AZTA

Azenta Inc · Q4 2024 earnings

Q4 2024 earnings · · Investor relations

Briefing

Azenta reported mixed Q4 2024 results with revenue down slightly but growth in core segments and margin expansion.

Azenta's Q4 2024 revenue was $170 million, a 1% decrease year-over-year. However, the combined Sample Management Solutions and Multiomics businesses grew 5% organically. The company reported a diluted EPS from continuing operations of ($0.10) and a non-GAAP diluted EPS of $0.18. They are pursuing the sale of B Medical Systems.

  • Revenue decreased by 1% year-over-year to $170 million.
  • Combined Sample Management Solutions and Multiomics businesses grew 5% organically.
  • Non-GAAP diluted EPS was $0.18, compared to $0.13 in the prior year.
  • The company announced plans to sell B Medical Systems.

Headline financials

Total Revenue

$170M

Previous: $172M-1.3%
EPS (adj)

$0.18

Previous: $0.13+38.5%
Adjusted EBITDA margin

10.7%

No prior period
Adjusted gross margin

47.0%

No prior period
Adjusted operating margin

5.1%

No prior period
Operating margin

-3.1%

No prior period
Adjusted EBITDA

$16M

No prior period
Capital Expenditures

-$12.1M

Previous: -$10.2M-18.0%
Net Income

-$12.3M

Previous: $3.38M-464.2%
Operating Income

-$12M

Previous: -$16.6M+27.8%
Gross Profit

$69.4M

Previous: $68M+2.0%
R&D Expense

$8.41M

No prior period
Stock-Based Comp

$1.85M

Previous: -$715K+358.0%

Revenue & EPS history

Azenta · Revenue · Quarterly

$170M

Q4 2024-1.3%vs Q4 2023
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Forward guidance

Azenta expects total organic revenue growth in the range of 3% to 5% for fiscal year 2025, excluding B Medical Systems. Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.

Tailwinds

  • Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024.
  • Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024.
  • Focus on core revenue growth in Sample Management Solutions and Multiomics businesses.
  • Commitment to meaningfully expand margins.
  • Renewed focus on free cash flow.

Headwinds

  • Azenta does not provide forward-looking guidance on a GAAP basis.
  • Inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items.
  • Adjustments include transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, and other gains and charges.
  • These adjustments are not representative of the normal operations of the business.
  • Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-0.6%

Avg return

Earnings day

-0.1%

Avg return

5 days after

+0.4%

Avg return

30 days after

43%

28 / 65 earnings

Positive

+22.4%

Q4 2025

Best reaction

-23.4%

Q1 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026-21.6%-21.0%-6.1%
Q1 2026-23.4%-19.3%-34.2%
Q4 2025+22.4%+20.9%+14.8%
Q2 2025-0.7%+11.3%+13.1%
Q1 2025+3.4%-8.6%-16.0%
Q4 2024-2.9%-9.4%+0.2%
Q3 2024-4.9%-1.1%-15.4%
Q2 2024-4.8%-6.9%-2.1%
Q1 2024-4.0%-1.2%-2.0%
Q4 2023+14.6%+16.1%+27.2%
Q3 2023+21.8%+18.4%+11.0%
Q2 2023-19.8%-11.1%+0.0%
Q1 2023-20.8%-22.2%-29.7%
Q4 2022+15.8%+17.5%+25.8%
Q3 2022-10.3%-8.7%-23.8%
Q2 2022-4.0%+5.6%+8.9%
Q1 2022+5.6%-3.1%-7.0%
Q4 2021-7.6%-7.1%-16.7%
Q3 2021-4.0%-4.0%-3.5%
Q2 2021-7.3%-7.1%-2.9%
Q1 2021-2.8%-0.3%-4.2%
Q4 2020+9.7%+12.8%+19.9%
Q3 2020+17.8%+21.2%+13.2%
Q2 2020-15.4%-12.3%-3.9%
Q1 2020-1.4%+6.7%-15.1%
Q4 2019+7.8%+5.5%-7.7%
Q3 2019-15.7%-17.0%-14.1%
Q2 2019+18.5%+23.4%+15.6%
Q1 2019+0.9%-5.3%-0.4%
Q4 2018-11.6%-10.9%-13.6%
Q3 2018-7.2%-5.8%+22.3%
Q2 2018+8.4%+12.5%+31.4%
Q1 2018-3.4%-9.5%-2.4%
Q4 2017-23.3%-21.2%-28.8%
Q3 2017-8.1%+0.9%+6.6%
Q2 2017+6.0%+9.4%+16.3%
Q1 2017+16.9%+20.6%+20.0%
Q4 2016+7.7%+11.7%+20.1%
Q3 2016-3.3%-5.4%-1.7%
Q2 2016-7.3%
Q1 2016-1.7%
Q4 2015-0.2%
Q3 2015+11.2%
Q2 2015-0.5%
Q1 2015-5.1%
Q4 2014+6.0%
Q3 2014+2.7%
Q2 2014+1.1%
Q1 2014-1.3%
Q4 2013+2.9%
Q3 2013-4.0%
Q2 2013+2.7%
Q1 2013+2.5%
Q4 2012+1.3%
Q3 2012-13.8%
Q2 2012-1.1%
Q1 2011+7.2%
Q1 2012+7.2%
Q4 2009+2.8%
Q2 2011+2.8%
Q4 2011+2.8%
Q4 2010-0.1%
Q3 2010-0.1%
Q3 2011-0.1%
Q2 2010-6.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro